This phenomenon was potentially associated with intratumor heterogeneity, selective pressure and clonal evolution, resulting in the diversity of resistance mechanisms in EGFR-mutated NSCLC with osimertinib resistance. Here, EGFR is linked to non-small cell lung carcinoma.